BridgeMD
New treatment option for Thyroid Cancer
Official title Adjuvant Radiotherapy in High Risk Locally Advanced DTC
ClinicalTrials.gov ID: NCT06558981
What this study is testing
- What it's testing
- This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 80
You may be able to join if
- The patient voluntarily joined this study and signed an informed consent form;
- Age: ≥ 14 years old,\<80 years old, male or female not limited;
- Histopathological diagnosis of differentiated thyroid cancer;
- Surgical total or near total thyroidectomy;
- The surgery did not achieve R0 resection, and R1/ R2 resection was performed. The volume of residual tumor in R2 resected patients is less than 2cm3;
You likely can't join if
- Previously received radiation therapy for the head and neck area;
- Differentiated thyroid cancer with poorly differentiated, or undifferentiated components;
- There is distant metastasis;
- Previously received 131I treatment;
- Previously received or currently receiving targeted therapy, immunotherapy, chemotherapy;
- Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous...
See the full eligibility criteria
- The patient voluntarily joined this study and signed an informed consent form;
- Age: ≥ 14 years old,\<80 years old, male or female not limited;
- Histopathological diagnosis of differentiated thyroid cancer;
- Surgical total or near total thyroidectomy;
- The surgery did not achieve R0 resection, and R1/ R2 resection was performed. The volume of residual tumor in R2 resected patients is less than 2cm3;
- The main organ functions are normal;
- Good compliance and cooperation with follow-up.
- Previously received radiation therapy for the head and neck area;
- Differentiated thyroid cancer with poorly differentiated, or undifferentiated components;
- There is distant metastasis;
- Previously received 131I treatment;
- Previously received or currently receiving targeted therapy, immunotherapy, chemotherapy;
- Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ...
- Pregnant or lactating women;
- Other physical illnesses that affect patients' ability to receive standard treatment;
- According to the researchers' assessment, there may be other factors that could force the people to terminate the study, such as suffering from other serious illnesses (including mental illnesses) that require...
- Individuals with claustrophobia who are unable to undergo radiation therapy;
- Patients deemed unsuitable for inclusion by other attending physicians.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.